BSE filing, NSE: COLINZ. Summary written from the filing by ALFA Finder's alert engine.
Colinz Laboratories Ltd: key numbers
- Share price
- ₹69.00
- Market cap
- ₹17.38 Cr
- Revenue (annual)
- ₹6.14 Cr
- Net profit (annual)
- ₹0.51 Cr
- P/E (TTM)
- 6.2×Sector 46.5×
- Promoter holding
- 50.60%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Colinz Laboratories Ltd
All →Colinz Laboratories Board Meeting Date
Colinz Laboratories scheduled a board meeting for October 29, 2026, to consider and approve the unaudited financial results for the quarter ended September 30, 2026.
Colinz Laboratories Other Announcement
The company filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Colinz Laboratories Other Announcement
Colinz Laboratories Ltd submitted a non-applicability declaration for Related Party Transaction disclosures for the quarter ended September 30, 2026. The company claims exemption under Regulation 15(2).
Colinz Laboratories Annual General Meeting
Colinz Laboratories held its 40th Annual General Meeting on September 22, 2026, where shareholders considered financial statements and director appointments.
Colinz Laboratories Open Offer: ₹3.54 Cr
Colinz Laboratories Ltd issued a Post Offer Advertisement for an Open Offer. The offer closed with only 6 shares tendered out of a proposed 6,54,966 shares.
- Value
- ₹3.54 Cr
Colinz Laboratories Annual Report
Colinz Laboratories Limited has submitted its 40th Annual Report for the financial year 2025-26. The report includes notice for the Annual General Meeting scheduled for September 22, 2026.
Other other announcement announcements
All →Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.
Avience Biomedicals Other Announcement
Avience Biomedicals confirmed corporate governance compliance is not applicable, as it is SME-listed on NSE Emerge. No quarterly governance report is required for September 2026.